Therapeutics News and Research

RSS

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.

28 Mar 2011

UT Southwestern receives $36.7 million CPRIT grant for cancer studies

The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.

28 Mar 2011

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.

25 Mar 2011

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

25 Mar 2011

SeraCare launches new HIV panel

SeraCare Life Sciences, a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announces the launch of its new Worldwide HIV Performance Panel.

25 Mar 2011

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

VisualSonics introduces Vevo LAZR system to advance cancer research

VisualSonics Inc., a leader in real-time, in vivo, high-resolution micro-imaging systems and a wholly-owned subsidiary of SonoSite Inc., today announced the launch of the Vevo LAZR Photoacoustics Imaging system for the advancement of cancer research in the pre-clinical imaging market.

25 Mar 2011

Researchers identify gene that can predict hypersensitivity to epilepsy drug

Research published this week in the New England Journal of Medicine. A multinational team of scientists led by the Royal College of Surgeons in Ireland and the University of Liverpool has identified a gene that could indicate if epilepsy patients starting a common drug treatment are likely to experience side-effects ranging from a mild skin irritation to the potentially fatal Steven-Johnson Syndrome.

25 Mar 2011

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, positive top-line results.

25 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.

24 Mar 2011

Molecular Therapy journal publishes Mirna's new tumor suppressor miRNA mimics data

Mirna Therapeutics, Inc. announced today the publication of new results in the journal Molecular Therapy demonstrating how a neutral lipid emulsion facilitates the systemic delivery of tumor suppressor miRNA mimics and reduces the tumor burden in the lungs of mice.

24 Mar 2011

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics.

24 Mar 2011

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company has been selected to present key Tovaxin data at the upcoming American Academy of Neurology 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.

23 Mar 2011

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011

Genetic errors in women linked to increased risk of preeclampsia

Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.

23 Mar 2011

Roundup: HHS Secretary's ability to waive Medicaid requirements; Kansas seeks more funding for disability programs

U.S. Health and Human Services Secretary Kathleen Sebelius has broad legal authority to waive Medicaid maintenance-of-effort requirements, according to a memo from the Congressional Research Service to the U.S. Senate Finance Committee.

23 Mar 2011

Therapeutics News and Research

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

UT Southwestern receives $36.7 million CPRIT grant for cancer studies

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

SeraCare launches new HIV panel

BrainStorm provides review of recent accomplishments for shareholders, investors

VisualSonics introduces Vevo LAZR system to advance cancer research

Researchers identify gene that can predict hypersensitivity to epilepsy drug

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Diabetes management accepted for coverage by Chemical Abstracts

Aradigm fourth quarter revenue is $144,000 for 2010

Molecular Therapy journal publishes Mirna's new tumor suppressor miRNA mimics data

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

SGEN, Abbott enter collaboration agreement for ADC products

Genetic errors in women linked to increased risk of preeclampsia

Roundup: HHS Secretary's ability to waive Medicaid requirements; Kansas seeks more funding for disability programs

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News